Brain’s Kappa-Opioid Switch: New Map Reveals How Dynorphin Circuits Drive Depression and Anxiety

Deep inside the brain, a molecular system best known for producing the dysphoric, joyless side of opioid drugs is emerging as one of the most promising targets for treating depression and anxiety. A comprehensive review published in the Journal of Cellular and Molecular Medicine maps, in unprecedented anatomical detail, how the kappa-opioid receptor and its natural partner, the peptide dynorphin, operate across the neural circuits that govern fear, reward and mood. The work arrives at a moment of genuine clinical momentum: kappa-opioid receptor antagonists are advancing through trials as candidate antidepressants, and researchers increasingly argue that understanding exactly where and how this system acts in the brain is the key to using it therapeutically.

The kappa-opioid receptor/dynorphin system has long been understood as a kind of counterweight to the mu-opioid receptor system. Where mu-opioid stimulation produces the euphoria and addictive pull of drugs like morphine, kappa-opioid activation produces dysphoria, aversion and negative emotional states. Animal studies have repeatedly shown that blocking the receptor with antagonists such as norbinaltorphimine or JDTic produces anxiolytic and antidepressant-like effects, while activating it induces the opposite. Yet the review emphasizes that this simple picture conceals a far more complicated reality. In some circumstances kappa-opioid stimulation can actually be rewarding, and mice engineered to lack the receptor throughout the central nervous system do not uniformly show reduced anxiety. The receptor couples to multiple downstream signalling pathways with different outcomes, and different ligands can preferentially engage some of those pathways over others. Even more surprisingly, while the receptor normally couples to inhibitory Gi proteins and hyperpolarizes neurons, under certain conditions it can switch to Gs coupling and depolarize them instead.

To untangle this complexity, the review organizes the evidence around two major brain circuits. The first is the prefrontal cortex-hippocampus-amygdala circuit, central to fear learning, fear extinction and anxiety. The second is the ventral tegmental area-nucleus accumbens pathway, the brain’s principal reward machinery. Both are heavily implicated in major depressive disorder and anxiety disorders, and both are richly endowed with kappa-opioid receptors whose distribution, cellular targets and behavioural roles differ markedly from region to region.

Within the prefrontal cortex, the review highlights a striking degree of circuit specificity. In rodents, dynorphin-expressing neurons are found in the infralimbic cortex, in both somatostatin-positive inhibitory interneurons and glutamatergic projection cells. Notably, the rodent medial prefrontal cortex contains a higher proportion of somatostatin-positive than parvalbumin-positive interneurons, suggesting the kappa system carries particular weight in this region. Stimulating the receptor in the prelimbic cortex produces place aversion, and agonist administration into the medial prefrontal cortex silences potentials evoked by basolateral amygdala inputs. Recent work suggests the system acts as a kind of switching mechanism: by inhibiting kappa-positive neurons and certain interneuron classes, it can selectively amplify signals arriving from kappa-negative projections, such as those from the ventral hippocampus, effectively re-weighting the importance of competing information streams during threat processing.

The hippocampus tells its own story. The dentate gyrus holds the highest density of dynorphin and kappa-opioid receptors in the structure, and stressful events increase hippocampal dynorphin expression, with sudden surges associated with reduced synaptic transmission and prolonged suppression of long-term potentiation at key synapses. In the Wistar-Kyoto rat, a genetic model of depression, prodynorphin mRNA peaks in the dentate gyrus, and direct injection of the antagonist norbinaltorphimine into the CA3 region produces antidepressant effects in a learned helplessness paradigm. The system also intersects with brain-derived neurotrophic factor, a molecule central to synaptic plasticity and antidepressant action: blocking kappa receptors raises hippocampal BDNF expression, while the agonist U50488 suppresses it and worsens depressive symptoms in mice. Standard antidepressants including imipramine, fluoxetine and citalopram can counteract the agonist-induced BDNF reduction in the hippocampus, though not in the prefrontal cortex.

In the amygdala, the receptor’s role in fear memory is particularly vivid. Fear conditioning upregulates kappa-opioid receptors in the basolateral amygdala, and successful fear extinction brings expression back down. Infusing the antagonist JDTic into the basolateral and central amygdala reduces fear expression, while basolateral infusion alone is anxiolytic. The agonist U50488 increases the activity of basolateral pyramidal neurons through a MAPK-pathway-dependent mechanism, likely by inhibiting local inhibitory interneurons, and presynaptic receptors on basolateral outputs dampen glutamatergic signalling to both the nucleus accumbens and the prefrontal cortex. The system also ties directly into the stress axis: blocking kappa receptors in the basolateral amygdala counteracts the anxiogenic effects of corticotropin-releasing factor, which appears to activate the dynorphin machinery through its type 1 receptor. Within the central amygdala, a subset of CRF-producing inhibitory neurons releases GABA under baseline conditions to restrain anxiety, but under aversive conditions they co-release dynorphin and CRF, tipping the balance toward fear and aversion.

The reward circuitry of the ventral tegmental area and nucleus accumbens adds another layer. In the ventral tegmental area, kappa receptors sit presynaptically on dopaminergic neurons, and acute stress disrupts a nitric-oxide-mediated feedback loop that normally restrains dopamine firing. Under stress, constitutive receptor activation silences the inhibitory GABAergic neurons, allowing dopaminergic neurons to fire more rapidly, an effect reversed by norbinaltorphimine. In the nucleus accumbens, the two principal medium spiny neuron populations express different opioid peptides: dynorphin in reward-processing D1 neurons, enkephalins in aversion-processing D2 neurons. Depression models show that blocking kappa receptors directly in the accumbens alleviates depressive behaviour, and inhibiting CREB, the transcription factor that upregulates prodynorphin there, produces similar benefit. In a morphine-withdrawal model of depression, microdoses of antagonist injected into the accumbens were antidepressant, and chronic systemic administration extended the effect for up to two weeks.

Human evidence, though sparser, is strikingly consistent with the animal work. Postmortem studies find reduced prodynorphin mRNA in the amygdala of individuals with major depressive disorder, particularly in its parvicellular and magnocellular divisions and the amygdalohippocampal area, and a similar reduction in the periamygdaloid cortex of heroin users, a shared molecular signature linking addiction and depression through the same circuitry. In rhesus macaques, the kappa antagonist navacaprant protects against stress-induced working memory impairments, apparently by interfering with receptor-modulated norepinephrine and dopamine release in the prefrontal cortex. Depressed patients, meanwhile, require greater prefrontal activation than healthy controls to achieve comparable task performance, hinting at the circuit-level inefficiency that kappa-directed drugs might help relieve.

The review is candid about the field’s limitations. Most evidence comes from rodent studies that frequently neglect sex, age and social status, variables that demonstrably matter. Depression is more prevalent in females, oestrogen signalling can regulate kappa/mu receptor heterodimer formation, and sex-dependent differences in receptor localization and function have been reported in both rodents and humans. Adolescent rodents respond differently to kappa manipulation than adults, and in non-human primates receptor availability varies with social rank. Human imaging faces its own constraints: functional MRI offers only indirect measures of neuronal activity, while positron emission tomography with kappa-selective radiotracers is limited by cost, radiation exposure and small samples. These gaps explain why optogenetics, chemogenetics and electrophysiology in animals remain indispensable, even as they cannot fully reproduce the subjective texture of human affective illness.

What emerges is a system far richer than a simple molecular brake on mood. The kappa-opioid receptor/dynorphin system acts differently in each node of these circuits, on different cell types, at different developmental stages and under different hormonal and social conditions, sometimes inhibiting and sometimes, paradoxically, exciting. That complexity is precisely what makes it therapeutically interesting: rather than globally suppressing or enhancing a neurotransmitter, kappa-directed drugs could in principle retune specific switches within the fear and reward circuitry. As clinical trials of kappa antagonists progress, the review argues, future studies must build sex, age and social context into their designs from the start, because the same receptor that drives dysphoria in one context may hold the key to resilience in another.

Subject of Research: The role of the kappa-opioid receptor/dynorphin system in modulating prefrontal-hippocampal-amygdala and mesolimbic circuits involved in depression and anxiety

Article Title: The Role of Kappa‐Opioid Receptor/Dynorphin System in Modulating Neural‐Circuits of Depression and Anxiety—A Review

Article References: Ciotei, C., Păunescu, H., Lungu, C., Marica, A.-A., Tănase, M. F., Marin, R.-C., Costescu, M., Fulga, I., & Coman, O. A. (2026). The Role of Kappa‐Opioid Receptor/Dynorphin System in Modulating Neural‐Circuits of Depression and Anxiety—A Review. Journal of Cellular and Molecular Medicine, 30(19), Article e71392. https://doi.org/10.1111/jcmm.71392

Image Credits: AI Generated

DOI: 10.1111/jcmm.71392

Keywords: kappa-opioid receptor, dynorphin, depression, anxiety, amygdala, nucleus accumbens, ventral tegmental area, prefrontal cortex, hippocampus, KOR antagonists, neural circuits, BDNF